Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.68 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.68 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12006856 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL16731962 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18458103 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL10079544 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL16731963 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18458105 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL12006829 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18473436 | 1.00 | OPRM1 (0.68) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL18720200 | 0.91 | OPRM1 (0.62) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| SCHEMBL20077640 | 0.91 | OPRM1 (0.64) | OPRM1OPRD1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348430-B2 | Production of opioid analgesics | ACURA PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | claimed |
| US-20060167258-A1 | Production of opioid analgesics | SCHUTTE, JOHN | 2006-07-27 | — | — | US | claimed |
| US-4940586-A | Skin permeation enhancer compositions using sucrose esters | ALZA CORPORATION (US) | 1990-07-10 | — | — | US | claimed |
| EP-3071575-B1 | PREPARATION OF NORMORPHINANS | SpecGx LLC (US) | 2019-11-13 | — | — | EP | disclosed |
| US-10406153-B2 | Process for the preparation of benzhydrocodone hydrochloride | NORAMCO, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-10155771-B2 | Selective reduction of morphinan alkaloids | NORAMCO, INC. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180055836-A1 | PROCESS FOR THE PREPARATION OF BENZHYDROCODONE HYDROCHLORIDE | NORAMCO, INC. (US) | 2018-03-01 | — | — | US | disclosed |
| EP-2328899-B1 | PROCESSES FOR THE SYNTHESIS OF FIVE AND SIX MEMBERED HETEROCYCLIC RINGS | MALLINCKRODT LLC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-9808452-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9657027-B2 | Processes for making hydrocodone, hydromorphone and their derivatives | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-9657028-B2 | Processes for making hydrocodone, hydromorphone and their derivatives | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-23 | — | — | US | disclosed |
| US-4423221-A | ANALGESICS, NARCOTIC ANTAGONIST | SISA PHARMACEUTICAL LABORATORIES, INC. (US) | 1983-12-27 | — | — | US | disclosed |
| EP-0019254-B1 | 7-METHYL AND 7-METHYL-8-LOWER ALKYL B/C CIS OR TRANS MORPHINAN-6-ONE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | MILES LABORATORIES, INC. (US) | 1982-09-01 | — | — | EP | disclosed |
| EP-0023576-B1 | 7- AND 7,8-SUBSTITUTED 4,5-ALPHA-EPOXYMORPHINAN-6-ONES AND THERAPEUTICALLY ACTIVE COMPOSITIONS CONTAINING THEM | MILES LABORATORIES, INC. (US) | 1982-06-23 | — | — | EP | disclosed |
| US-4272541-A | 7,8 and 7-8 Substituted 4,5α-epoxymorphinan-6-one compounds, and methods of treating pain and drug dependence with them | MILES LABORATORIES, INC. (US) | 1981-06-09 | — | — | US | disclosed |
| EP-0023576-A1 | 7- and 7,8-substituted 4,5-alpha-epoxymorphinan-6-ones and therapeutically active compositions containing them | MILES LABORATORIES, INC. (US) | 1981-02-11 | — | — | EP | disclosed |
| US-4242514-A | Method for the introduction of a methyl group into the 7 position of the morphinan nucleus | MILES LABORATORIES, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4242514-A | Method for the introduction of a methyl group into the 7 position of the morphinan nucleus | MILES LABORATORIES, INC. (US) | 1980-12-30 | — | — | US | disclosed |
| US-4230712-A | ANALGESIC AND NARCOTIC ANTAGONISTS | MILES LABORATORIES, INC. (US) | 1980-10-28 | — | — | US | disclosed |
| US-4025521-A | REDUCTION OF THEBAINE WITH POTASSIUM IN LIQUID AMMONIA | SHARPS ASSOCIATES (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155771-B2 | Selective reduction of morphinan alkaloids | QDPR, CA5B, COX5B | OPRM1 56/4885OPRD1 161/4885OPRK1 70/4885 |
| US-20180055836-A1 | PROCESS FOR THE PREPARATION OF BENZHYDROCODONE HYDROCHLORIDE | DBH, DHPS, PAH | OPRM1 74/4885OPRD1 27/4885OPRK1 34/4885 |
| US-10406153-B2 | Process for the preparation of benzhydrocodone hydrochloride | DBH, DHPS, PAH | OPRM1 74/4885OPRD1 27/4885OPRK1 34/4885 |
| US-20060167258-A1 | Production of opioid analgesics | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.